Logo image
Back
Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant, rOv-ASP-1
Journal article   Open access   Peer reviewed

Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant, rOv-ASP-1

Jiu Jiang, Erin M. Fisher, Mark Concannon, Sara Lustigman, Hao Shen and Donna M. Murasko
Vaccine, v 34(7), pp 887-892
10 Feb 2016
DOI: https://doi.org/10.1016/j.vaccine.2016.01.003
PMID: 26795365
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.vaccine.2016.01.003View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze),  Open

Abstract

Adjuvant Aged Influenza Vaccine Virus
•Influenza-specific antibody levels were significantly increased after immunization with TIV+rOv-ASP-1 in aged mice.•rOv-ASP-1 was superior to the conventional adjuvant alum in inducing specific IgG after TIV immunization in aged mice.•Co-administration of rOv-ASP-1 induced cross-reactive antibody and enhanced cross-protection. Immunization is the best way to prevent seasonal epidemics and pandemics of influenza. There are two kinds of influenza vaccines available in the United States: an inactivated vaccine (TIV) and an attenuated vaccine; however, only TIV is approved for immunization of the elderly population. While the aged population has the highest rate of influenza vaccination, the protective efficacy is low as evidenced by elderly individuals having the highest mortality associated with influenza. Recently, we reported that an adjuvant derived from the helminth parasite Onchocerca volvulus, named O. volvulus activation-associated secreted protein-1 (Ov-ASP-1), can significantly enhance the protective efficacy of an inactivated vaccine (TIV) in young adult mice. In the current study, we examined whether this recombinant Ov-ASP-1 (rOv-ASP-1) can enhance the efficacy of TIV in aged mice as well. While primary immunization with TIV alone produced only a low level of influenza-specific antibodies (total IgG, IgG1, and IgG2c) in aged mice, the antibody levels were significantly increased after immunization with TIV+rOv-ASP-1. More importantly, the level of the total IgG in aged mice administered TIV+rOv-ASP-1 was comparable to that of young adult mice immunized with TIV alone. Co-administration of rOv-ASP-1 induced a low level of cross-reactive antibody and enhanced the protective efficacy of TIV in aged mice, reflected by significantly increased survival after challenge with a heterologous influenza virus. rOv-ASP-1 was also superior to the conventional adjuvant alum in inducing specific IgG after TIV immunization in aged mice, and in conferring protection after challenge. These results demonstrate that rOv-ASP-1 may serve as a potential adjuvant for influenza vaccine to improve the efficacy of protection in the elderly.

Metrics

13 Record Views
12 citations in Web of Science
12 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Immunology
Medicine, Research & Experimental
Logo image